Home / all / Fufang Huanlinxian’an Pian or Compound Cyclophosphamide Tablets for malignant lymphoma. (24 tablets*3 boxes/lot).
  • Fufang Huanlinxian’an Pian or Compound Cyclophosphamide Tablets for malignant lymphoma. (24 tablets*3 boxes/lot).
  • Fufang Huanlinxian’an Pian or Compound Cyclophosphamide Tablets for malignant lymphoma. (24 tablets*3 boxes/lot).
  • Fufang Huanlinxian’an Pian or Compound Cyclophosphamide Tablets for malignant lymphoma. (24 tablets*3 boxes/lot).
  • Fufang Huanlinxian’an Pian or Compound Cyclophosphamide Tablets for malignant lymphoma. (24 tablets*3 boxes/lot).

Fufang Huanlinxian’an Pian or Compound Cyclophosphamide Tablets for malignant lymphoma. (24 tablets*3 boxes/lot).

Quantity
ADD TO CART
BUY IT NOW
Detail
Customer Reviews


NAMES

Fufang Huanlinxian’an Pian

Compound Cyclophosphamide Tablets

复方环磷酰胺片

Fufang Huanlinxian’an Pian (Compound Cyclophosphamide Tablets)for malignant lymphoma

ACTIONS
Antineoplastic agents.

INDICATIONS
Mainly used for malignant lymphoma, acute lymphoblastic leukemia, lung tumours, various sarcomas, solid tumors and ovarian tumor.

INGREDIENTS
Cyclophosphamide,Ginsenoside of stems and leaves.

PROPERTIES
Enteric-coated tablets, after removal of the coating was yellow or tan.

Spec.
50mg24 tablets/box.

USAGE AND DOSAGE
Oral,adult,1 tablet per time, 3-4 times daily.

ADVERSE REACTION
1.Myelosuppression is the most common toxicity. Leukocytes are often the lowest at 10 to 14 days after administration, and return to normal at the 21st day. Thrombocytopenia is rarer than other alkylating agents. Common side effects include nausea and vomiting. Severity is related to dose.

2.Cyclophosphamide metabolites can produce severe hemorrhagic cystitis, and large amounts of fluid can be avoided. This product can also cause bladder fibrosis.

3.When a large dose of cyclophosphamide (50 mg/kg body weight) is administered use with a large amount of liquid at the same time, it can produce water toxicity, and furosemide can be given at the same time to prevent it.

4.Cyclophosphamide can cause reproductive system toxicity, such as menopause or lack of sperm. Early pregnancy can cause teratogenicity.

5.Long-term administration of cyclophosphamide can produce secondary tumors.

6.Compound cyclophosphamide can reduce severe immunosuppression.

7.When used in the treatment of leukemia or lymphoma, prone to hyperuricemia and uric acid nephropathy.

8.Uncommon side effects include fever, allergies, skin and nail pigmentation, mucosal ulcers, elevated alanine aminotransferase, urticaria, oropharyngeal sensation, or blurred vision..

CONSTRAINDICATION
Constraindiction during pregnancy and lactation period.

PRECAUTION
1.The following conditions should be used with caution: bone marrow suppression, history of gout, liver damage, infection, renal function damage, infiltration of bone marrow by tumor cells, history of urethrhoeous stones, previous chemotherapy or radiation therapy.

2. The white blood cell count and classification, platelet count, renal function (urea nitrogen creatinine elimination rate), liver function (serum bilirubin, alanine aminotransferase), and serum uric acid level should be regularly checked during medication.

3. When the renal function is impaired, the dose of cyclophosphamide should be reduced to 1/2 to 1/3 of the therapeutic dose.

4.When patients with leukemia or lymphoma have uric acid nephropathy, the following methods can be used to prevent: rehydration, basal urine, and/or allopurinol.

5.When tumor cells infiltrate the bone marrow or previous chemotherapy or radiation therapy causes severe bone marrow suppression, the dose of cyclophosphamide should be reduced to 1/2 to 1/3 of the therapeutic dose.

6.If there is obvious leukopenia (especially neutropenia) or thrombocytopenia, compound cyclophosphamide tablets should be discontinued.

7.Interference with the diagnosis: This product can reduce the serum cholinesterase, blood and urine uric acid levels increase.

DRUG INTERACTIONS
If use with the other drugs at the same time may occur drug interactions,details please consult your physician or pharmacist.

VALIDITY
24 months.

STORAGE
Preserve in tightly closed containers,stored in a cool and dry place.

APPROVAL NUMBER
State medical permitment number.H22026738.

Manufactured
TONGHUA MAOXIANG PHARMACEUTICAL CO.,LTD

General Cautions:
Keep away from animals and children.
This product has not been evaluated by the FDA. It is not intended to
diagnose, treat, cure, or prevent any disease.
We highly recommend that you consult with a Traditional Chinese Medical
practitioner or physician before taking any products or if you have any questions regarding your health.

Tips: part of the goods frequent replacement of packaging, such as goods and pictures are not exactly the same, please refer to the goods you receive.